Asenapine has been approved by the FDA for the acute treatment of adults with schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults [REF].
In the European Union and the UK asenapine is only licensed for use as a treatment for acute mania in bipolar I disorder [REF].